VANCOUVER, BC, Dec. 22, 2023 /PRNewswire/ -- BioVaxys Technology Corp. (CSE:BIOV) (FRA: 5LB) (OTCQB:BVAXF) ("BioVaxys" or "Company") announced today that it has executed a non-binding Letter of Intent ("LOI") to acquire the core platform technology and entire immunotherapeutics intellectual property portfolio of discovery, preclinical development, and Phase II clinical study stage assets in oncology and other immunological fields, including active licenses with several pharma companies, formerly owned by an unnamed biotechnology company and now held by the unnamed company's former secured creditor. Under the terms of LOI, BioVaxys has been granted exclusivity while the parties work in good faith on the drafting of a definitive agreement.
Investors are advised to use caution in trading the Company's shares while discussions on the definitive agreement are underway. There is no certainty and there can be no assurance that the parties will reach agreement on the definitive acquisition agreement or will complete any transaction. We advise shareholders to await further developments.
About BioVaxys Technology Corp.
BioVaxys Technology Corp. (www.biovaxys.com), a biopharmaceuticals company based in Vancouver, Canada, is developing BVX-0918, a personalized immunotherapeutic vaccine using our proprietary HapTenix© 'neoantigen' tumor cell construct platform for treating refractive late-stage ovarian cancer and other tumor types. The Company is ...